Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
1.
Exp Parasitol ; 262: 108775, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38735518

ABSTRACT

The limited activity of the traditional medications against T. spiralis encysted larvae handicaps complete cure of trichinellosis till now due to decreased permeability and absorption through tissues. MOX is listed worldwide for prevention and treatment of several internal and external nematodes. Consequently, the aim of this work was to investigate the effect of moxidectin versus ivermectin on experimental acute and chronic trichinellosis and to illuminate the potential mechanisms of their effects. 105 Mice were divided into four groups; Group I: Uninfected healthy control; Group II: Infected untreated control; Group III: Infected and treated with IVM and Group IV: Infected and treated with MOX. The groups (II, III and IV) were later subdivided equally into three subgroups (a, b, and c) according to the stage of treatment. Parasitological counting of adults and larvae besides immune-histopathological examination of intestines and muscles were done. Results exhibited that both IVM and MOX succeeded in reducing adults and larvae counts with higher potential of MOX in both intestinal and muscle phase. The preeminence of MOX was indicated by decreased inflammation, a significant reduction in the microvascular density (CD31 immunostaining) as well as a reduction in the percentage of fibroblast activation protein (FAP) immunostaining in muscle tissues. Accordingly, the current work recommends moxidectin as an innovative treatment for trichinellosis.


Subject(s)
Ivermectin , Macrolides , Trichinellosis , Animals , Trichinellosis/drug therapy , Trichinellosis/prevention & control , Trichinellosis/parasitology , Macrolides/therapeutic use , Macrolides/pharmacology , Mice , Ivermectin/therapeutic use , Ivermectin/pharmacology , Chronic Disease , Trichinella spiralis/drug effects , Acute Disease , Larva/drug effects , Female , Male , Anthelmintics/therapeutic use , Anthelmintics/pharmacology , Muscle, Skeletal/parasitology , Muscle, Skeletal/pathology
2.
Pharm Dev Technol ; 28(6): 571-583, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37306671

ABSTRACT

The aim was to enhance the dissolution rate and in vivo efficacy of flubendazole against trichinella spiralis. Flubendazole nanocrystals were developed by controlled anti-solvent recrystallization. Saturated flubendazole solution was prepared in DMSO. This was injected into phosphate buffer (pH 7.4) containing Aerosil 200, Poloxamer 407 or sodium lauryl sulphate (SLS) while mixing using paddle mixer. The developed crystals were separated from DMSO/aqueous system by centrifugation. The crystals were characterized using DSC, X-ray diffraction and electron microscopy. The crystals were suspended in Poloxamer 407 solution and dissolution rate was monitored. Optimal formulation was administered to Trichinella spiralis infected mice. Administration protocol attacked the parasite in intestinal, migrating and encysted phases. The crystals were spherical nanosized with formulation employing 0.2% Poloxamer 407 as stabilizer being optimum with size of 743.1 nm. DSC and X-ray supported particle size reduction with partial amorphization. Optimal formulation showed fast dissolution to deliver 83.1% after 5 min. Nanocrystals provided complete eradication of intestinal Trichinella and reduced larval count by 90.27 and 85.76% in migrating and encysted phases compared with marginal effect in case of unprocessed flubendazole. The efficacy was clearer from improved histopathological features of the muscles. The study introduced nano-crystallization for enhanced dissolution and in vivo efficacy of flubendazole.


Subject(s)
Trichinella spiralis , Mice , Animals , Solubility , Poloxamer , Dimethyl Sulfoxide
3.
Exp Parasitol ; 248: 108515, 2023 May.
Article in English | MEDLINE | ID: mdl-36958594

ABSTRACT

Latent toxoplasmosis mostly reactivates which could result in acute encephalitis. Chronic toxoplasmosis treatments are severely constrained by Toxoplasma cyst resistance. Novel therapeutic approaches are therefore becoming more essential. In this study, the effects of levamisole (LEVA) and spiramycin on the early and late stages of experimental toxoplasmosis are investigated. MATERIALS AND METHODS: Seventy-five Me49 Toxoplasma gondii infected Swiss albino mice were divided into five groups; (GI): noninfected control group; (GII): infected untreated control group; (GIII): infected- LEVA treated group; (GIV): infected and received combination of spiramycin and LEVA and (GV): infected-spiramycin treated group. The impact was assessed through brain cyst count by Quantitative Real-Time Polymerase Chain Reaction (PCR), interferon gamma (IFN-γ) assay, histopathological study, and total blood counts. RESULTS: The progression of chronic toxoplasmosis could only be partially controlled by using either levamisole or spiramycin as a separate drug. The combined spiramycin and levamisole treatment significantly decreased the burden of Toxoplasma brain cyst, increased IFN-γ level, total blood parameters and improved the histopathological features especially at the late stage of infection. IN CONCLUSION: Levamisole effectively modulated Toxoplasma-induced immune responses, resulting in chronic toxoplasmosis remission. Further clinical trials will be needed to study the effect of these combination in HIV/AIDS (human immunodeficiency virus) patients with toxoplasmosis.


Subject(s)
Spiramycin , Toxoplasma , Toxoplasmosis , Animals , Mice , Humans , Spiramycin/pharmacology , Spiramycin/therapeutic use , Levamisole/pharmacology , Levamisole/therapeutic use
4.
Acta Trop ; 239: 106830, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36638878

ABSTRACT

Toxoplasma gondii is a zoonotic intracellular protozoan parasite and its therapeutic limitations are one of its major problems. L-citrulline is an organic compound that has beneficial effects on many diseases. The purpose of this study was to assess the impact of L-citrulline, alone or in combination with sulfamethoxazole-trimethoprim (SMZ-TMP) on acute toxoplasmosis caused by Toxoplasma gondii RH virulent strain. In our study, 60 Swiss albino mice were divided into two main groups; the control group and the infected treated group, which was subdivided into group IIa: infected treated with L-citrulline, group IIb: infected treated with SMZ-TMP, and group IIc: infected treated with L-citrulline combined with SMZ-TMP. The effects of treatment were assessed by parasitological study, electron microscopic study of tachyzoites, and histopathological study of the liver. Moreover, ELISA measurement of the serum level of Interferon-gamma, Interleukin 10, Nitric oxide, and apoptotic markers was used. It was noticed that L-citrulline combined with SMZ-TMP significantly increased the survival time of infected mice with a significant decrease in the number of tachyzoites compared to the other groups. Moreover, it increased the levels of measured cytokines and serum anti-apoptotic proteins Bcl-2 and improved the extent of liver cell damage associated with a decrease in inflammatory infiltration. In conclusion, L-citrulline supplementation was found to be effective against acute toxoplasmosis, especially when combined with SMZ-TMP as it has multifactorial mechanisms; nitric oxide production, anti-inflammatory, anti-apoptotic, and immune stimulator.


Subject(s)
Toxoplasma , Toxoplasmosis , Animals , Mice , Citrulline/therapeutic use , Citrulline/pharmacology , Nitric Oxide , Toxoplasmosis/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
5.
Acta Trop ; 237: 106748, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36368413

ABSTRACT

Giardiasis is an intestinal protozoal disease caused by Giardia lamblia (G. lamblia) which is a major worldwide health problem due to development of resistance to commonly used drugs. Therefore, it is necessary to identify an effective drug for giardiasis. This study aimed to assess the therapeutic role of L-citrulline against giardiasis in experimental animals. 40 male Swiss Albino weaned rats were used in this study, divided into four groups. Group I: normal control; group II: infected un-treated; group III: infected and treated with L-citrulline and Group IV: infected and treated with metronidazole. The efficacy was evaluated by counting Giardia trophozoites in the intestinal mucosa and cysts in the stool of infected rats. Histopathological analyses, immunohistochemistry expression of inducible nitric oxide synthase (iNOS) in the small intestine tissues were performed. Along with, serum IL6, the intestinal arginase enzyme level and giardial flavohemoglobin (flavoHb) expression were measured. L-citrulline administration reduced the mean number of G. lamblia cysts and trophozoites, serum IL-6, and intestinal arginase enzyme levels. Furthermore, the intestinal brush border was restored, with a reduction in the inflammatory infiltrate and an increase in iNOS activity. Moreover, there was a significant decrease in flavoHb gene expression in both the L-citrulline and metronidazole treated groups. Thus L-citrulline is effective in NO production therefore it has a therapeutic potential in controlling giardiasis.


Subject(s)
Cysts , Giardia lamblia , Giardiasis , Male , Mice , Rats , Animals , Giardiasis/drug therapy , Citrulline/pharmacology , Citrulline/therapeutic use , Metronidazole/pharmacology , Metronidazole/therapeutic use , Arginase , Giardia , Trophozoites , Arginine/pharmacology , Immunity
6.
Pathog Dis ; 80(1)2022 11 12.
Article in English | MEDLINE | ID: mdl-36264282

ABSTRACT

Human trichinellosis is a serious disease with no effective treatment till now. Recently, the protective immunity induced by parasite-derived extracellular vesicles (EVs) are studied for some parasites such as Echinostoma caproni. The current study aimed to investigate the novel Trichinella spiralis-derived EVs as a potential vaccine candidate for the first time in a mouse model. Trichinella spiralis EVs were isolated and identified using transmission electron microscopy, gel electrophoresis, protein content measurements, and beads-based flow cytometry. Vaccination was done by subcutaneous injection of two doses of 3.5 µg T. spiralis-derived EVs. We observed a significant reduction in T. spiralis adult worm and muscle larval counts in mice immunized with T. spiralis-derived EVs (EVs-Ts group) and controlled inflammatory changes in the intestine and muscles. The EVs-Ts group showed a higher level of IFN- γ, whereas the IL-4 secretion was elevated more in the EVs group (EVs group) and showed a lower level after challenge with T. spiralis infection (EVs-Ts group). This implies a mixed Th1/Th2 immune response with obvious Th1 polarization. Moreover, elevation of serum T. spiralis-specific IgG was reported. In conclusion, this preliminary study provides T. spiralis EVs as a promising candidate for future development of anti-Trichinella vaccine.


Subject(s)
Extracellular Vesicles , Trichinella spiralis , Vaccines , Humans , Mice , Animals , Trichinella spiralis/physiology , Larva , Mice, Inbred BALB C
7.
Exp Parasitol ; 238: 108277, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35613683

ABSTRACT

Giardia lamblia (G. lamblia) is an important cause of severe malabsorption, weight loss, physical and mental retardation especially in infants and children throughout the world. Metronidazole (MTZ) is the standard drug used for their treatment which possesses several drawbacks with low efficacy. Gold nanoparticles possess a broad-spectrum antimicrobial activity and could be considered as a future alternative to many microbial agents. This study aimed to evaluate the anti-Giardia effect of gold nanoparticles as an alternative to MTZ. This study was done on 70 experimentally albino rats that were divided into three main groups with seven subgroups (each of 10 rats). The effect of MTZ and gold nanoparticles as single or combined therapy were evaluated. The effect was assessed by counting Giardia fecal cysts in the stool and trophozoites in the intestinal wash, histopathological, transmission and scanning electron microscopic examinations of the small intestinal tissues. Toxic tests of biochemical parameters of liver and kidney function were also performed. A significant reduction of the parasite number in the stool and small intestinal sections was apparent in treated infected rats compared with the infected non-treated ones. Gold nanoparticles showed the best result and the highest effect in the eradication of the parasite from the stool and the intestine with marked improvement in the intestinal mucosal injury caused by G. lamblia trophozoites. Gold nanoparticles had a toxic effect on the liver, with no kidney toxicity. Nanogold can be considered as a potential therapeutic agent and as a promising alternative therapy for G. lamblia infection. Further studies using various dosages with different durations of treatment with gold nanoparticles can be tested on Giardia lamblia infection.


Subject(s)
Giardia lamblia , Giardiasis , Metal Nanoparticles , Animals , Giardia , Giardiasis/drug therapy , Giardiasis/parasitology , Gold/therapeutic use , Humans , Metal Nanoparticles/therapeutic use , Metronidazole/pharmacology , Metronidazole/therapeutic use , Rats , Trophozoites
8.
Int J Immunopathol Pharmacol ; 35: 20587384211054036, 2021.
Article in English | MEDLINE | ID: mdl-34696610

ABSTRACT

BACKGROUND AND OBJECTIVE: Living organisms respond to physical, chemical, and biological threats with a potent inflammatory response which alters organ cell signaling and leads to dysfunction. We evaluated the therapeutic effect of bone marrow-based mesenchymal stromal cell (BM-MSC) transplanted in rats to preserve tissue integrity and to restore homeostasis and function in the pancreatitis experimental pattern. METHODS: This study involved 40 adult male Wister rats. Repeated L-arginine injections caused chronic pancreatitis (CP), leading to the development of pancreatic damage and shifting the intracellular signaling pathways. Rats were then infused with BM-MSC labeled with PKH26 fluorescent linker dye for 12 weeks. RESULTS: Cell-surface indicators of BM-MSCs such as CD 90 and CD29 were expressed with the lack of CD34 expression. BM-MSC treatment considerably improved the alterations induced in a series of inflammatory markers, including IL-18, TNF-α, CRP, PGE2, and MCP-1. Furthermore, improvement was found in digestive enzymes and lipid profile with amelioration in myeloperoxidase activity. BM-MSC treatment also regulated the (TGF-/p-38MPAK/SMAD2/3) signaling factors that enhances repair of damaged pancreatic tissue, confirmed by reversed alteration of histopathological examination. CONCLUSION: our results further bring to light the promise of cell transplant therapy for chronic pancreatitis.


Subject(s)
Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Pancreatitis, Chronic/therapy , Amylases/metabolism , Animals , Arginine , C-Reactive Protein/analysis , Cytokines , Dinoprostone/blood , Lipase/metabolism , Lipid Metabolism , Male , Pancreas/enzymology , Pancreas/pathology , Pancreatitis, Chronic/blood , Pancreatitis, Chronic/chemically induced , Pancreatitis, Chronic/metabolism , Rats, Wistar , Smad2 Protein/metabolism , Smad3 Protein/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
9.
Drug Dev Ind Pharm ; 47(4): 663-672, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33826458

ABSTRACT

WHO considers praziquantel (PZQ) as the drug of choice for treatment of Schistosoma mansoni infection but this requires high dose due to poor solubility and first pass metabolism. The aim of this work was to optimize nanostructured lipid carriers (NLCs) for enhanced PZQ oral delivery. The optimization involved testing the effect of surface charge of NLCs. NLCs comprised precirol ATO as solid lipid with oleic acid, Span 60 and Tween 80 as liquid components. Dicetyl phosphate and stearyl amine were the negative and positive charging agents, respectively. NLCs were prepared by microemulsification technique and were characterized. The schistosomicidal activity of PZQ loaded NLCs was monitored in vitro and in vivo using infected mice. PZQ showed high entrapment efficiency in all types of NLCs (ranged from 93.97 to 96.29%) with better PZQ loading in standard NLCs. This was clarified by thermal analysis which reflected displacement of PZQ by charging agents. In vitro schistosomicidal study revealed the superiority of PZQ loaded positively charged NLCs (LC50 and LC95 equal 0.147 and 0.193 µg/ml respectively) with traditional and negatively charged NLCs being inferior to simple PZQ solution after short incubation period. Scanning electron micrographs showed that PZQ loaded positively charged NLCs resulted in more intense ultrastructural changes in worms. The superiority of positively charged NLCs was confirmed by in vivo assessment as they showed better improvement in histopathological features of the liver of the infected mice compared with other formulations. The study introduced positively charged NLCs as promising carriers for oral delivery of PZQ.


Subject(s)
Nanostructures , Schistosomicides , Animals , Drug Carriers , Lipids , Mice , Praziquantel/pharmacology , Schistosomicides/pharmacology
10.
Parasitol Res ; 118(1): 219-234, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30421348

ABSTRACT

Praziquantel (PZQ) is recommended by the WHO as the first line in treatment of schistosomiasis. Unfortunately, it exhibits low oral bioavailability which can compromise its efficacy. Nanostructures showed promising potential to overcome this problem. Accordingly, the aim of this study was to investigate the effect of niosomal encapsulation of PZQ on its activity on Schistosoma mansoni in vitro and in vivo. PZQ was encapsulated in niosomal formulation comprising span 60, cholesterol with peceol being included as absorption enhancer. The in vitro work determined the schistosomicidal activity and morphological changes after incubation with drug solution or PZQ-niosomes. The in vivo study utilized infected mice which received PZQ orally as solution or as niosomes. The activity was assessed by monitoring egg and worm count in addition to histopathological and immunohistochemical studies. The in vitro studies revealed that niosomes alone caused a 30% death of adult parasites and caused completely coiled body, destruction, and peeling of tubercles and spines, with flattening and effacement of gynecophoric canal, blebbing with niosomes vesicles attached to it. Niosomes containing PZQ at a concentration of 0.001 µg/ml increased the death from 30 to 50% with the corresponding PZQ solution causing only 10% death. The in vivo study reflected of niosome-PZQ over PZQ solution as indicated from significant reduction of adult worm count, hepatic and intestinal egg depositions, hepatic granuloma size, and numbers, with marked reduction of vascular endothelial growth factor expression. The study introduced niosomes as promising carriers for enhanced activity of PZQ.


Subject(s)
Liver Diseases/drug therapy , Praziquantel/administration & dosage , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Schistosomicides/administration & dosage , Animals , Biological Availability , Female , Humans , Intestines/parasitology , Intestines/pathology , Liposomes/chemistry , Liver Diseases/genetics , Liver Diseases/metabolism , Liver Diseases/parasitology , Male , Mice , Praziquantel/chemistry , Schistosoma mansoni/growth & development , Schistosomiasis mansoni/genetics , Schistosomiasis mansoni/metabolism , Schistosomiasis mansoni/parasitology , Schistosomicides/chemistry , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
11.
Environ Entomol ; 47(4): 1047-1056, 2018 08 11.
Article in English | MEDLINE | ID: mdl-29878175

ABSTRACT

The American serpentine leaf miner, Liriomyza trifolii (Burgess) (Diptera: Agromyzidae), is a perennial pest of leguminous crops in the Mediterranean region. A life table was constructed for L. trifolii infesting broad bean, Vicia faba L., in northern Egypt. Key factor analysis was used to rank sources of immature mortality over two seasons. Leaf miners had three successive generations, and a partial fourth, in each year, with peak abundance in March-April. Less than 15 and 22% of L. trifolii survived to adult in seasons one and two, respectively. The largest contributor of immature leaf miner mortality in both seasons was unknown (41.2 and 39.1% of total mortality, respectively), and likely comprised a combination of abiotic factors, parasitoid-inflicted mortality (host-feeding), and predation. Parasitism was second, contributing 36.2 and 35.6% of total mortality in the two seasons, respectively, primarily due to larval parasitism by Diglyphus isaea (Walker) (Hymenoptera: Eulophidae), and low levels of larval-pupal parasitism by Opius pallipes Wesmael (Hymenoptera: Braconidae) and Halticoptera circulus (Walker) (Hymenoptera: Pteromalidae). Residual mortality resulted from malformed pupae or failed adult emergence. Key factor analysis revealed malformation to be the major cause of pupal mortality. Sequential regression confirmed that unknown mortality and D. isaea were the top stage-specific factors, both acting on larvae. Parasitoid abundance tracked host abundance across generations, but density dependence was not observed for any mortality factor, and the magnitudes of regression slopes were small. The results indicate the potential importance of conservation biological control in management of L. trifolii, given that naturally occurring parasitoids and other biotic/abiotic factors exert significant mortality on immature leaf miners.


Subject(s)
Diptera/physiology , Diptera/parasitology , Herbivory , Host-Parasite Interactions , Vicia faba , Wasps/physiology , Animals , Egypt , Factor Analysis, Statistical , Larva/growth & development , Larva/parasitology , Life Tables , Longevity , Population Dynamics , Pupa/growth & development , Pupa/parasitology
12.
Bone Joint J ; 100-B(4): 549-556, 2018 04 01.
Article in English | MEDLINE | ID: mdl-29629589

ABSTRACT

Aims: The purpose of this study was to evaluate the long-term outcome of adolescents with cerebral palsy who have undergone single-event multilevel surgery for a flexed-knee gait, followed into young adulthood using 3D motion analysis. Patients and Methods: A total of 59 young adults with spastic cerebral palsy, with a mean age of 26 years (sd 3), were enrolled into the study in which their gait was compared with an evaluation that had taken place a mean of 12 years (sd 2) previously. At their visits during adolescence, the children walked with excessive flexion of the knee at initial contact and surgical or therapeutic interventions were not controlled between visits. Results: Based on the change in flexed-knee gait over approximately ten years, improvements were seen in increased Gait Deviation Index (p < 0.001) and decreased flexion of the knee at initial contact (p < 0.001). Greater popliteal angle (p < 0.001), reduced Gross Motor Function Measure section D (p = 0.006), and reduced speed of gait (p = 0.007) suggested a mild decline in function. Quality-of-life measures showed that these patients fell within normal limits compared with typical young adults in areas other than physical function. Conclusion: While some small significant changes were noted, little clinically significant change was seen in function and gait, with gross motor function maintained between adolescence and young adulthood. Cite this article: Bone Joint J 2018;100-B:549-56.


Subject(s)
Cerebral Palsy/physiopathology , Cerebral Palsy/surgery , Gait Disorders, Neurologic/surgery , Gait , Knee Joint/physiopathology , Orthopedic Procedures , Adolescent , Adult , Follow-Up Studies , Gait Disorders, Neurologic/etiology , Gait Disorders, Neurologic/physiopathology , Humans , Patient Reported Outcome Measures , Physical Examination , Quality of Life , Range of Motion, Articular , Retrospective Studies , Time and Motion Studies , Treatment Outcome , Young Adult
13.
Breast Cancer ; 25(3): 297-302, 2018 May.
Article in English | MEDLINE | ID: mdl-29285674

ABSTRACT

BACKGROUND: Hepatitis C virus (HCV) has the lymphotropic feature that is supposed to be the reason of related extrahepatic manifestation. HCV viral oncoproteins may participate in the regulation of some gene expression that has been implicated in tumorigenesis. Our aim is to evaluate the HCV-NS4 circulating levels in breast cancer (BC) and to investigate its relation with BC tumor aggressiveness. METHODS: This study was performed among 158 Egyptian women (120 with BC and 38 with benign breast diseases). ELISA was used for detection of anti-HCV antibodies, HCV-NS4, fibronectin, and CA 15-3. RESULTS: No association between HCV detection in this group of BC patients (27.5% in BC vs. 23.7% in breast benign diseases, P = 0.687). Among HCV-infected patients, the mean HCV-NS4 serum level in BC was significantly higher than benign group (61.7 µg/mL vs. 33.9 µg/mL, P = 0.0005). Fibronectin levels were higher (P = 0.014) in patients infected with HCV than noninfected BC patients. Elevated HCV-NS4 levels were associated with tumor severity features like large size, late stages, high grades, and infiltrated lymph nodes. The elevated levels of HCV-NS4 (> 40 µg/mL) yielded an estimated odds ratio (95% confidence intervals) of 2.5 (0.98-6.36), 1.2 (0.44-3.33), 1.9 (0.53-7.00), and 2.5 (0.87-7.33) for developing large size, late stages, high grades, and infiltrated lymph nodes, respectively. Interestingly, HCV-NS4 levels significantly correlated with other BC tumor marker like CA15-3 (r = 0.535; P = 0.0009) and fibronectin (r = 0.432; P < 0.0001). CONCLUSIONS: HCV-NS4 appears to be associated with BC progression features. Oncologists treating such BC patients should consider HCV screening to enable the early identification and to prevent progression of the disease.


Subject(s)
Breast Neoplasms/blood , Hepacivirus/isolation & purification , Hepatitis C/blood , Viral Nonstructural Proteins/blood , Adult , Aged , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Breast Neoplasms/virology , Carcinogenesis/immunology , Disease Progression , Egypt/epidemiology , Enzyme-Linked Immunosorbent Assay , Female , Fibronectins/blood , Gene Expression Regulation, Neoplastic/immunology , Hepacivirus/immunology , Hepacivirus/metabolism , Hepatitis C/epidemiology , Hepatitis C/immunology , Hepatitis C Antibodies/blood , Hepatitis C Antibodies/immunology , Humans , Incidence , Middle Aged , Mucin-1/blood , Neoplasm Grading , Neoplasm Staging , Viral Nonstructural Proteins/immunology
14.
Ann Oncol ; 27(6): 975-984, 2016 06.
Article in English | MEDLINE | ID: mdl-27052650

ABSTRACT

BACKGROUND: For men with advanced castration-resistant prostate cancer (CRPC), several treatment options are available, including androgen receptor (AR) pathway inhibitors (abiraterone acetate, enzalutamide), taxanes (docetaxel, cabazitaxel) and the radionuclide (radium-223). However, cross-resistance is a clinically relevant problem. Platinum compounds have been tested in a number of clinical trials in molecularly unselected prostate cancer patients. Advances in CRPC molecular profiling have shown that a significant proportion of patients harbour DNA repair defects, which may serve as predictive markers for sensitivity to platinum agents. OBJECTIVE: To systematically identify and analyse clinical trials that have evaluated platinum agents in advanced prostate cancer patients. METHODS: PubMed was searched to identify published clinical trials of platinum agents in advanced prostate cancer. The PRIMSA statement was followed for the systematic review process. Identified trials are analysed for study design, statistical plan, assessments of anti-tumour activity and the potential value of predictive biomarkers. RESULTS: A total of 163 references were identified by the literature search and 72 publications that met the selection criteria were included in this review; of these 33 used carboplatin, 27 cisplatin, 6 satraplatin, 4 oxaliplatin and 2 other platinum compounds. Overall, anti-tumour activity varies in the range of 10%-40% for objective response and 20%-70% for PSA decline ≥50%. Response seemed highest for the combinations of carboplatin with taxanes or oxaliplatin with gemcitabine. The interpretation of the clinical data is limited by differences in response criteria used and patient populations studied. CONCLUSION: Platinum compounds have moderate anti-tumour activity in molecularly unselected patients with advanced prostate cancer. Translational evidence of DNA repair deficiency should be leveraged in future studies to select prostate cancer patients most likely to benefit from platinum-based therapy.


Subject(s)
Platinum Compounds/therapeutic use , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/radiotherapy , Androgen Receptor Antagonists/adverse effects , Androgen Receptor Antagonists/therapeutic use , Benzamides , Cisplatin/adverse effects , Cisplatin/therapeutic use , Clinical Trials as Topic , Combined Modality Therapy , Docetaxel , Humans , Male , Nitriles , Phenylthiohydantoin/adverse effects , Phenylthiohydantoin/analogs & derivatives , Phenylthiohydantoin/therapeutic use , Platinum Compounds/adverse effects , Prostatic Neoplasms, Castration-Resistant/pathology , Radium/therapeutic use , Taxoids/adverse effects , Taxoids/therapeutic use , Treatment Outcome
15.
Ann Oncol ; 26(2): 354-62, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25467017

ABSTRACT

BACKGROUND: Continuation or 'switch' maintenance therapy is commonly used in patients with advancd non-small-cell lung cancer (NSCLC). Here, we evaluated the efficacy of the telomerase inhibitor, imetelstat, as switch maintenance therapy in patients with advanced NSCLC. PATIENTS AND METHODS: The primary end point of this open-label, randomized phase II study was progression-free survival (PFS). Patients with non-progressive, advanced NSCLC after platinum-based doublet (first-line) chemotherapy (with or without bevacizumab), any histology, with Eastern Cooperative Oncology Group performance status 0-1 were eligible. Randomization was 2 : 1 in favor of imetelstat, administered at 9.4 mg/kg on days 1 and 8 of a 21-day cycle, or observation. Telomere length (TL) biomarker exploratory analysis was carried out in tumor tissue by quantitative PCR (qPCR) and telomerase fluorescence in situ hybridization. RESULTS: Of 116 patients enrolled, 114 were evaluable. Grade 3/4 neutropenia and thrombocytopenia were more frequent with imetelstat. Median PFS was 2.8 and 2.6 months for imetelstat-treated versus control [hazard ratio (HR) = 0.844; 95% CI 0.54-1.31; P = 0.446]. Median survival time favored imetelstat (14.3 versus 11.5 months), although not significantly (HR = 0.68; 95% CI 0.41-1.12; P = 0.129). Exploratory analysis demonstrated a trend toward longer median PFS (HR = 0.43; 95% CI 0.14-1.3; P = 0.124) and overall survival (OS; HR = 0.41; 95% CI 0.11-1.46; P = 0.155) in imetelstat-treated patients with short TL, but no improvement in median PFS and OS in patients with long TL (HR = 0.86; 95% CI 0.39-1.88; and HR = 0.51; 95% CI 0.2-1.28; P = 0.145). CONCLUSIONS: Maintenance imetelstat failed to improve PFS in advanced NSCLC patients responding to first-line therapy. There was a trend toward a improvement in median PFS and OS in patients with short TL. Short TL as a predictive biomarker will require further investigation for the clinical development of imetelstat.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Indoles/therapeutic use , Lung Neoplasms/drug therapy , Maintenance Chemotherapy/methods , Niacinamide/analogs & derivatives , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Disease-Free Survival , Enzyme Inhibitors/therapeutic use , Female , Humans , In Situ Hybridization, Fluorescence , Kaplan-Meier Estimate , Lung Neoplasms/mortality , Male , Middle Aged , Niacinamide/therapeutic use , Oligonucleotides , Proportional Hazards Models , Telomerase/antagonists & inhibitors , Telomere/pathology
16.
Microvasc Res ; 84(1): 81-5, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22487440

ABSTRACT

Bone morphogenetic proteins (BMPs) and their receptors play important roles in cellular processes such as proliferation, differentiation, migration and cell survival. It was also demonstrated that BMPs are involved in vasculogenesis and angiogenesis. In this study, we investigated the expression profile of BMP receptors in human umbilical vein endothelial cells (HUVECs) and determined the effect of BMP-2 on proliferation, migration, invasion, cell survival and tube formation. HUVECs express the type I BMP receptors ALK2, ALK3 and ALK6 and the type II receptor BMPR-II. Treatment of HUVECs with recombinant human BMP-2 induced migration, invasion and tube formation of HUVECs without affecting proliferation and apoptosis. Our data suggest that BMP-2 represents a chemoattractant and proangiogenic factor for HUVECs.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Bone Morphogenetic Protein Receptors, Type II/metabolism , Bone Morphogenetic Protein Receptors, Type I/metabolism , Human Umbilical Vein Endothelial Cells/drug effects , Apoptosis/drug effects , Biomarkers/metabolism , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Neovascularization, Physiologic/drug effects , Recombinant Proteins
17.
Urol Int ; 86(4): 383-7, 2011.
Article in English | MEDLINE | ID: mdl-21474914

ABSTRACT

Partial circumcision techniques frequently lead, on account of the remaining foreskin, to functional complications and unsatisfactory cosmetic results requiring re-operation. A series of pictures taken from our own sample of patients illustrates the problem. Review of the literature also attests to higher complication rates after partial circumcision. From a medical point of view, complete circumcision is preferable.


Subject(s)
Circumcision, Male/methods , Foreskin/surgery , Child, Preschool , Humans , Male , Penis/surgery , Postoperative Complications
18.
Diabet Med ; 23(2): 122-7, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16433708

ABSTRACT

AIMS: To improve the quality of care in children with Type 1 diabetes who have limited access to specialized diabetes care in rural areas, by providing a mobile diabetes education and care team, affiliated with a University hospital paediatric diabetes centre. METHODS: A cohort of 107 children and their families from eight rural hospitals was followed between July 2000 and July 2002. Parameters on quality of metabolic control (HbA(1c), hospitalization rate and number of episodes of severe hypoglycaemia), diabetes knowledge and quality of life at baseline (t(0)), 6 weeks (t(1)) and 6 months (t(2)) after the interventions were measured. RESULTS: Mean HbA(1c) was 7.9 +/- 1.4% at t(0). The proportion of HbA(1c) values < 6.8% increased significantly (P < 0.05) and of values > 8.0% decreased significantly (P < 0.01) at t(1) and t(2). The rate of hospitalization fell significantly by 9.4%, from 16.2% at baseline to 6.8% at t(2) (P < 0.05). The children reported significantly better diabetes-specific quality of life (P < 0.05) and higher self-esteem (P < 0.01) after the intervention. Theoretical diabetes knowledge was increased both in the short and long term (P < 0.05). CONCLUSIONS: The intervention improved metabolic control, diabetes knowledge and diabetes-specific quality of life. We conclude that high-quality diabetes care in a rural area can be provided by a mobile diabetes education and care team.


Subject(s)
Ambulatory Care/methods , Diabetes Mellitus, Type 1/rehabilitation , Patient Education as Topic/methods , Adolescent , Child , Cohort Studies , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/metabolism , Female , Glycated Hemoglobin/analysis , Health Knowledge, Attitudes, Practice , Hospitalization , Humans , Hypoglycemia/complications , Male , Patient Satisfaction , Quality of Life , Rural Health
19.
Article in English | MEDLINE | ID: mdl-16329667

ABSTRACT

Cardiac magnetic resonance imaging (CMR) permits a detailed look at the myocardium in patients with recent onset heart failure. Late-enhancement CMR provides information that is similar to that obtained by the naked eye of a pathologist. Myocardial scarring is endocardial in myocardial infarction, but it is epicardial in myocarditis and intramyocardial in hypertrophic cardiomyopathy. Thus, the distinction between these entities is possible by depicting scar via late-enhancement CMR and observing myocardial function by cine magnetic resonance imaging. Moreover, non-invasive follow-up--and hence observation of the healing or remodelling process--can be achieved using CMR. New CMR pulse sequences also permit depiction of myocardial oedema, which may occur early in patients with myocarditis and may be the only sign of the disease in the absence of necrosis. It is anticipated that cardiac MRI will become a standard diagnostic technique in patients with new onset of heart failure, left-ventricular hypertrophy or clinical symptoms suggestive of myocarditis.


Subject(s)
Cardiomyopathies , Magnetic Resonance Imaging , Myocarditis , Biopsy , Cardiomyopathies/diagnosis , Cardiomyopathies/pathology , Cardiomyopathies/physiopathology , Heart/anatomy & histology , Heart/physiology , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Myocarditis/diagnosis , Myocarditis/pathology , Myocarditis/physiopathology , Myocardium/pathology , Statistics as Topic
20.
Oral Microbiol Immunol ; 20(3): 154-62, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15836516

ABSTRACT

BACKGROUND: Oral warts, caused by human papillomavirus (HPV), and oral hairy leukoplakia (OHL) caused by Epstein-Barr virus (EBV), are common oral manifestations in HIV-infected persons. Although both conditions occur most often with reduced blood CD4+ T-cell numbers, oral warts and OHL rarely occur simultaneously, suggesting that dysfunctions in other secondary local immune parameters are also involved. The present study evaluated tissue-associated proinflammatory and T-helper cytokine and chemokine mRNA expression and the presence of T cells in each lesion. METHODS: Biopsies were taken from lesion-positive and adjacent lesion-negative sites of HIV+ persons with oral warts or OHL and lesion-negative sites from HIV+ persons who were oral HPV or EBV DNA-positive (matched controls). Cytokine/chemokine mRNA expression was quantified by real-time polymerase chain reaction. CD3, CD4, and CD8 cells were identified by immunohistochemistry. RESULTS: No differences were detected in tissue-associated cytokine/chemokine mRNA expression in warts or OHL when compared to lesion-negative sites. Immunohistochemical analysis of T cells showed CD8+ cells exclusively, but few cells were present in either lesion. No differences were detected between lesion-positive and -negative control sites of each pathologic condition. CONCLUSION: Little evidence was found for local immune reactivity to either oral warts and OHL, suggesting that CD4+ T cells are a primary host defense against both oral warts and OHL, but with nonimmune factors potentially responsible for the divergent prevalence of each.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , Leukoplakia, Hairy/immunology , Warts/immunology , AIDS-Related Opportunistic Infections/virology , CD3 Complex/analysis , CD4 Antigens/analysis , CD8 Antigens/analysis , Chemokines/analysis , Cytokines/analysis , Herpesvirus 4, Human/genetics , Humans , Immunohistochemistry , Leukoplakia, Hairy/virology , Papillomaviridae/genetics , Polymerase Chain Reaction , RNA, Messenger/isolation & purification , Statistics, Nonparametric , Warts/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...